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Elective radiation of the contralateral, radiographically negative neck contributes to head and neck radiotherapy treatment toxicity. Before the advent of intensity-modulated radiation therapy, radiation of the contralateral neck required the administration of significant doses to the major contralateral salivary glands (parotid and submandibular). With intensity-modulated radiation therapy, the dose to the salivary glands can be reduced, and although a corresponding improvement in the parotid salivary flow rate can be measured, a patient-reported improvement in xerostomia-related quality of life is not always detectable.
1,2 Although many factors contribute to symptomatic xerostomia, it seems that a dose to the contralateral salivary apparatus is a continuous variable, so that minimizing the dose further than accepted dosimetric constraints 3 may be expected to provide enhanced symptom relief. [4] [5] [6] [7] Limiting radiation to the ipsilateral side of the neck is a highly effective means to reduce damage to the contralateral salivary apparatus. In addition, unilateral neck radiotherapy can reduce the dose to the pharynx, which is proposed to be an independent predictor of treatment-related dysphagia. 8, 9 Unilateral neck radiotherapy in patients with selected lateralized tonsillar cancer has been practiced safely for decades. [10] [11] [12] Ideal candidates seem to have primary tumors with no greater than minimal involvement of an adjacent structure that drains to the bilateral neck (base of tongue and soft palate). 13 The potential increased risk of contralateral neck metastases secondary to advanced ipsilateral regional disease is difficult to characterize because, in the past, most patients with advanced regional disease tended to have larger primary tumors. In the most often quoted analysis, 10 no patient with ipsilateral treatment of N2 to N3 disease developed a contralateral recurrence. However, it is noteworthy that there were few patients with N2 to N3 cancer in that report because bilateral therapy was delivered to almost all due to the concern that bulky ipsilateral nodal involvement precipitates aberrant, contralateral nodal drainage. 14 The clinical rationale for unilateral neck radiotherapy is based upon patients treated from 1970 to 1991. Since the early 1990s, rates of tobacco use in the United States have decreased. 15 There has been a corresponding decrease in most cancers of the upper aerodigestive tract, with the exception of a rise in tumors of the oropharynx. 16 This parallels an increasing incidence of human papillomavirus (HPV)-associated cancers that are most prevalent in the oropharynx. 17 HPV-related oropharyngeal cancer has a different presentation from HPV-negative oropharyngeal cancer characterized by smaller T classification by comparison to the N classification. 18 The emergence of a new type of squamous cell carcinoma of the oropharynx with more advanced nodal stage relative to a given T classification warrants reexamination of the question of unilateral radiotherapy. This article addresses the incidence trends of bilateral adenopathy in tonsillar cancer from 1988 to 2008 to determine whether bilateral nodal involvement has become more common in tonsillar cancer as the proportion of HPV-associated cancers has increased and whether unilateral neck radiotherapy remains appropriate for HPV-associated oropharyngeal cancer.
MATERIALS AND METHODS
We obtained incidence data from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute for the years 1988 to 2008. We queried the SEER 9 registries. The SEER registries report data on patient demographics, primary tumor site, tumor morphology, stage at diagnosis, and treatment. The SEER registries were strategically selected to maximize representation of the overall U.S. population, reflecting approximately 28% of U.S. individuals. 19 The SEER database was interrogated for cases of tonsil and oropharyngeal cancer. Because of a coding change that occurred during the study period, it was necessary to divide the time frame into 2 separate intervals. For the years 1988 to 2003, SEER reports the American Joint Committee on Cancer 3rd edition stage, based primarily on the Extent of Disease 10 extension, nodes, and tumor size variables. 20 We chose tonsillar cancers coded as ''invasive cancer confined to one of the following subsites: anterior wall (including vallecula and lingual [anterior] surface of the epiglottis), 1 lateral wall, 1 posterior wall'' and ''localized, not otherwise specified'' as those that could potentially be amenable to unilateral therapy. For the years 2004 to 2008, SEER includes TNM staging according to the American Joint Committee on Cancer 6th edition, and we evaluated T1 and T2 tumors as those that were potentially amenable to unilateral therapy.
Cases per 1,000,000 were calculated using SEER*Stat software (http://seer.stat.gov/seerstat/index.html) and age adjusted to the U.S. 2000 population. The annual percent change (APC) was estimated for all instances using the weighted least squares method in the SEER*Stat software, version 7.0.4. The 95% confidence intervals for the APC were calculated to assess the precision of the obtained estimates using the Tiwari modification.
RESULTS
There has been a significant increase in the incidence of oropharyngeal cancer from 1988 to 2008 [percentage change (PC) 32%; APC 1.1%; p < .05]. The corresponding increased incidence of tonsillar cancer from the same time period has been profound (PC 54%; APC 1.7%: p < .05).
Primary tumor size trends
The number of primary tonsil tumors potentially amenable to unilateral therapy increased in both time frames evaluated (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (Tables 1  and 2 ).
Regional disease trends
In both time frames evaluated, the incidence of lymph node-negative tonsillar cancer is decreasing 7% ; p < .05). Analysis of the significantly increased incidence of N2 classification of neck disease suggests that it is due to a rising incidence of advanced ipsilateral disease (N2aN2b) rather than bilateral/contralateral disease (N2c), because the overall incidence of advanced Figure 1 ).
Small Primary Tonsillar Cancer Trends
The incidence of small primary tonsillar cancer without regional disease (the most common presentation in 1988), has been relatively stable (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) 
DISCUSSION
Survival for HPV-associated oropharyngeal cancers is far superior to that of non-HPV-associated oropharyngeal cancers. 17, 18, 21, 22 Current cooperative group trials are restricted by HPV status and efforts to reduce long-term toxicity are a major objective of these studies. 23 One approach to minimizing the toxicity of treatment for head and neck cancers is to define patterns of nodal spread and the safety of unilateral neck radiation. Because HPVrelated tonsillar cancer represents a distinct clinicopathologic entity from ''traditional risk factor tonsillar cancer,'' 24 the possibility that the nodal disease of these lesions more often spreads to the contralateral side of the neck warrants consideration.
The SEER data presented in this article and others 16, 18 demonstrates that the incidence and staging of oropharyngeal cancer is changing in the HPV era. Advanced regional disease among all T classifications is increasing. Small primary tonsillar cancer with advanced regional spread (eg, N2 classification in the neck) is rising from 7.2% to almost 11% on an annual basis. The cumulative increase over decades signifies that tonsillar cancer with advanced regional node disease is twice as common as it was fewer than 25 years ago. Analysis confined to small primary tonsil tumors with advanced node metastases demonstrates that their current incidence is 3 to 4 times that of 1988. All examined regional stage variables are increasing as a consequence of the general trend of the rising incidence of oropharyngeal and tonsillar cancer. These increases may critically affect locoregional treatment decisions. The increasing incidence of N2 neck disease reflects an increase in ipsilateral neck disease that is more pronounced than that of contralateral neck disease (N2aN2b: APC 10.6% vs N2c: APC 5.9%). We chose to report the incidence (per 1,000,000 patients) at the first and last year of each time period (rather than the percentage change) to demonstrate that the increased ipsilateral APC is magnified by the increased incidence in general. This shows that, despite the APC, the incidence of small primary tonsillar cancer with bilateral neck adenopathy is still less than 1 per 1,000,000 in 2008, as it was in 1988.
This approach is subject to typical SEER limitations including underrepresentation of minorities and regions, data entry error/incompleteness, and variations in data reporting. The SEER database was not intended to address such a nuanced issue, and it does not provide treatment information. Thus, some inferences are subject to a degree of uncertainty. There are certainly oropharyngeal cancers limited to 1 subsite that could be either midline or close to midline and not representative of patients classically receiving unilateral therapy. There are also tonsillar cancers that involve 2 subsites (which might be suitable for unilateral therapy). In addition, the coding change that necessitated a split of the years 1998 to 2008 into 2 unequal groups renders the analysis more cumbersome than one might prefer. However, important information may be derived.
The data do not support the contention that HPVrelated cancers show a higher rate of contralateral nodes than tumors caused by tobacco and alcohol abuse. Because the incidence of bilateral neck nodal disease is not increasing at a disproportionate rate from that of 20 years ago, adopting a policy of bilateral neck radiation in all patients with tonsillar cancer in the era of HPV-related cancers does not seem justified.
CONCLUSION
The incidence of advanced regional disease in small primary tonsillar cancer is increasing. This analysis of available population-based data supports the previously validated finding that small primary, lateralized tonsillar cancer is rarely associated with contralateral adenopathy. While contralateral adenopathy in small primary tonsillar cancer is increasing in prevalence, it seems to be a consequence of the rising rate of tonsillar cancer, rather than a special feature of HPV-related tumors. There is no current justification to alter the previously proposed indications for unilateral neck radiotherapy for lateralized tonsillar cancer.
